Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
fadraciclib (CYC065)
i
Other names:
CYC065, CYC 065, CYC-065
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(6)
News
Trials
Company:
Cyclacel
Drug class:
CDK2/9 inhibitor
‹
›
Associations
(6)
News
Trials
VERI cancer hierarchy
Reset Filters
MCL1 amplification
Endometrial Cancer
MCL1 amplification
Endometrial Cancer
CYC065
Sensitive: C3 – Early Trials
CYC065
Sensitive
:
C3
CYC065
Sensitive: C3 – Early Trials
CYC065
Sensitive
:
C3
CD133 positive
Glioblastoma
CD133 positive
Glioblastoma
CYC065 + SY‑079
Sensitive: D – Preclinical
CYC065 + SY‑079
Sensitive
:
D
CYC065 + SY‑079
Sensitive: D – Preclinical
CYC065 + SY‑079
Sensitive
:
D
CD44 positive
Glioblastoma
CD44 positive
Glioblastoma
CYC065 + SY‑079
Sensitive: D – Preclinical
CYC065 + SY‑079
Sensitive
:
D
CYC065 + SY‑079
Sensitive: D – Preclinical
CYC065 + SY‑079
Sensitive
:
D
BRCA1 2080delA + CCNE1 overexpression
Breast Cancer
BRCA1 2080delA + CCNE1 overexpression
Breast Cancer
CYC065
Sensitive: D – Preclinical
CYC065
Sensitive
:
D
CYC065
Sensitive: D – Preclinical
CYC065
Sensitive
:
D
BRCA1 2080delA
Breast Cancer
BRCA1 2080delA
Breast Cancer
olaparib + CYC065
Sensitive: D – Preclinical
olaparib + CYC065
Sensitive
:
D
olaparib + CYC065
Sensitive: D – Preclinical
olaparib + CYC065
Sensitive
:
D
BRCA1 R1443*
Breast Cancer
BRCA1 R1443*
Breast Cancer
olaparib + CYC065
Sensitive: D – Preclinical
olaparib + CYC065
Sensitive
:
D
olaparib + CYC065
Sensitive: D – Preclinical
olaparib + CYC065
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.